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Expression of the castration-induced clusterin protein is incompatible with the survival of human prostate cancer cells in tissues and in
cell culture. To investigate the fate of human prostate epithelial cells, when engineered to maintain expression of clusterin protein, we
have used an IRES-hyg vector and hygromycin selection. PC-3 prostate tumour cells were substantially more sensitive to clusterin
expression than nonmalignant PNT1a cells, showing multiple phenotypic changes including cell cycle arrest and increased apoptosis.
The results strengthen the hypothesis that clusterin expression is proapoptotic. Expression of exogenous clusterin in both cell types
resulted in its relocation from the cytoplasm and a nuclear accumulation of the protein, as was also seen in the same cells when
apoptosis was induced by etoposide treatment. To survive clusterin expression, the PC-3 tumour cells developed apoptosis-
inhibitory properties. This could have significance for the resistance of prostate cancers to chemo/radiotherapy, where clusterin
overexpression is observed.
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Clusterin is a highly conserved heterodimeric-secreted glycopro-
tein present in most animal tissues and body fluids (Rosenberg
and Silkensen, 1995). The protein has been implicated in several
biological processes, but a definitive mechanism of action and role
for this protein has not yet emerged. Clusterin is encoded by a
single gene located on chromosome 8p21–p12, a locus commonly
deleted in early stage prostate cancer (Macintosh et al, 1998). The
protein precursor of 65–70kDa is cleaved into two subunits, a and
b, linked by five disulphide bonds. The three-dimensional
arrangement of the subunits is currently unknown as no X-ray
crystallographic data are available for clusterin (because of the
ability of the protein to spontaneously aggregate in solution).
Since its first description in rat Sertoli cells in 1982 (Kissinger
et al, 1982) and in ram rete testis fluid (Blaschuk et al, 1983),
clusterin has been studied in several biological models, producing
conflicting data. Subsequently, it was found to be the most potently
induced gene in the rat ventral prostate after androgen ablation
(Bettuzzi et al, 1989). Several functions have been proposed for
clusterin, including chaperone activity (Lakins et al, 2002; Poon
et al, 2003), complement inhibition, membrane protection
(Silkensen et al, 1994), and recently, it has been described as a
biomarker of senescence (Bettuzzi et al, 1994; Petropoulou et al,
2001), Alzheimer’s disease (DeMattos et al, 2002), fertility (Ibrahim
et al, 2000) and cancer prognosis (Bettuzzi et al, 2000; Miyake et al,
2002). Despite the involvement in a variety of pathologies, the role
of clusterin in tumour progression and malignancy remains most
controversial. Increased (Hough et al, 2001; Miyake et al, 2002) or
decreased (Bettuzzi et al, 2000; Behrens et al, 2001; Zhang et al,
2003) expression was observed, depending on the organ or tissue
studied. We have shown previously that prostate tumour tissue
expresses significantly lower levels of clusterin compared to
adjacent normal prostate tissue (Bettuzzi et al, 2000).
Equally controversial results have been obtained with regard to the
role played by clusterin in apoptosis and cellular proliferation.
Although several reports found no correlation between clusterin
expression and cell proliferation (Petropoulou et al,2 0 0 1 ) ,a n d
suggest a possible antiapoptotic role for this gene (Miyake et al,2 0 0 0 ;
July et al, 2002), there is also evidence that clusterin can not only
affect the cell cycle (Bettuzzi et al, 1999; Bettuzzi et al, 2002; Zhou
et al, 2002), but also promote programmed cell death (Woolveridge
et al, 2001; Han et al, 2003). In particular, a proapoptotic role for
clusterin, facilitating the removal of severely damaged and genetically
unstable cells, has also been suggested (Yang et al, 2000).
Generally, clusterin expression has been found to be upregulated
in tissues undergoing regression, remodelling and apoptosis.
Recently, a nuclear localisation of clusterin was suggested as a
death signal (Yang et al, 1999, 2000) despite the presence of an
N-terminal secretory tag. Nuclear translocation of the protein
would derive from alternative splicing of clusterin mRNA,
producing a shorter (50-terminal truncated) messenger to produce
the nuclear form (Leskov et al, 2003). Short-term apoptotic
cytotoxicity, as well as a long-term clonogenic cytotoxicity
response, emerges from these data, identifying clusterin as a
death-inducing gene (Leskov et al, 2003).
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sOur previous work demonstrated that a transient overexpres-
sion of clusterin can affect the cell cycle in immortalised prostate
epithelial cells by decreasing their proliferation rate (Bettuzzi et al,
2002). We now describe the production of stable clones of both
SV40 immortalised normal prostate epithelial cells (PNT1a) and
bone metastatic cells from prostate cancer (PC-3), which can
overexpress clusterin. While the majority of cells die as a result of
clusterin overexpression, rare survivors can be isolated. These cell
clones have developed resistance to the apoptotic effects of
clusterin.
MATERIALS AND METHODS
Cell lines
PNT1a (Cussenot et al, 1991) is a nontumorigenic epithelial cell
line derived by SV40 immortalisation of normal prostate
epithelium. PC-3 is a prostatic carcinoma cell line with an
androgen-independent phenotype, purchased from the American
Tissue Culture Collection. PNT1a cells were maintained in RPMI
1640 (Gibco, Paisley, UK) containing 2mM glutamine and 10%
fetal calf serum (FCS) (Gibco, Pasley, UK); PC-3 cells were
maintained in Ham’s F12 medium (ICN, Irvine, CA, USA)
containing 2mM glutamine and 7% FCS.
Expression vectors
Full-length human clusterin cDNA was generated by RT–PCR
from normal human fibroblast total RNA using the primers
50-GACTCCAGAATTGGAGGCATG-30 and 50-ATCTCACTCCTCCC
GGTGCT-30 and cloned into pGEM T-easy (Promega, Southamp-
ton, UK).
From this vector, clusterin full-length cDNA was then subcloned
into the bicistronic expression vector pIREShyg1 (Accession
number U89672, Clontech, Oxford, UK) (Rees et al, 1996) to
produce pIRES-clu. Empty pIREShyg1 was used for generating
mock control clones (pIRES-hyg). Both expression vectors were
completely sequenced before use.
Transfection, selection of stable clones and etoposide
treatment
A total of 5 10
5 cells of each line were plated in 6-cm dishes
and transfected using the nonliposomal reagent FuGENE 6
(Roche, Lewes, UK), according to the manufacturer’s proto-
col. PNT1a and PC-3 cells were transfected with equimolar
amounts of endotoxin-free preparations of pIRES-clu or pIRES-
hyg (control). Transiently transfected cells were harvested 48h
after transfection.
Transfection efficiency was assessed by detection of green
fluorescence protein (GFP) expression by fluorescence microscopy
using the pEGFP-N1 vector (Clontech Laboratories, Inc., East
Meadow Circle, Palo Alto, CA, USA) in parallel transfection
experiments. Positively transfected cells were routinely more than
50% of the cell population.
For selection of stably transfected cell populations, hygromycin
B (Roche, Lewes, UK) was added to the culture medium 48h after
transfection at a concentration of 50mgml
 1 for PC-3 and
200mgml
 1 for PNT1a cells. These concentrations were predeter-
mined to give 100% cell kill within 10 days for each cell type.
Drug selection was maintained for 14 days, until visible
individual colonies were detected, fixed in paraformaldehyde 4%
and stained with Giemsa stain 0.4% (wv
 1) in buffered methanol
solution, pH 6.8, with stabilisers (Sigma, Dorset, UK).
Etoposide (Sigma, Dorset, UK) was added for 12h, at the
indicated doses, to parental PNT1a and PC-3 cells.
Cell proliferation assay and fluorescence-activated cell
sorter (FACS) analysis
Cell proliferation was studied using the cell proliferation reagent
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulphonate) (Roche, Lewes, UK) according to the
manufacturer’s protocol. Briefly, the number of viable cells, seeded
in triplicate in 96 well plates, was estimated on the basis of their
ability to metabolise tetrazolium salt WST-1 to formazan by
mitochondrial dehydrogenases. Quantification (OD) of the for-
mazan dye, which directly correlates to the metabolically active
number of cells, was carried on by a scanning microplate reader
(ELISA reader) MRX II, Dinex Technology.
Cell cycle analysis was evaluated by FACS (Beckman coulter
Epics
s XL) after staining the samples with propidium iodide.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 15min, permea-
bilised with 70% ethanol for 15min, washed in 50mM Tris-HCl
(pH 7.5)–150mM NaCl (TBS), and blocked in blocking solution
(1% casein blocking agent (Boehringer, Lewes, UK)–0.1% Tween
20 in TBS).
Staining was carried out with mouse monoclonal anti-hClusterin
alpha chain, clone 41D (Upstate Biotechnology, Lake Placid, NY,
USA) diluted 1:100 in blocking solution, followed by anti-mouse
IgG–Alexa 488 conjugate (Molecular Probes, Leiden, The Nether-
lands) diluted 1:200 in blocking solution. Cells were then counter-
stained with 1mgml
 1 40, 6-diamidino-2-phenylindole (DAPI,
Sigma, Dorset, UK) or DRAQ5t (Sigma, Dorset, UK) in TBS,
Figure 1 Colonies of hygromycin-resistant prostate epithelial cells
expressing clusterin are smaller than those expressing only hyg
r. Cell
colonies selected in cell culture dishes, fixed with paraformaldehyde 4% and
stained with Giemsa. Note the smaller size of the clu colonies (clu)
compared to the hyg colonies (hyg), after 14 days of selection with
hygromycin B. The figure shows a representative result obtained by
performing the experiment four times using different standard endo-free
plasmid preparations.
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swashed three times in TBS and observed for fluorescence using a
Nikon Eclipse fluorescent microscope. Images were captured using
the Openlab program (Coventry UK).
To detect Annexin-V binding, the cultures were washed in TBS
and incubated with Annexin-V–Alexa 568 (Boehringer, Lewes,
UK) according to the manufacturer’s protocol.
Western blotting
Whole cells were resuspended in buffer containing 1% SDS and 1%
dithiothreitol, heated to 1001C for 5min, fractionated by 10%
SDS–polyacrylamide gel electrophoresis and blotted to PVDF
membranes (Immobilon P, Millipore, Watford, UK). Clusterin was
PNT1a-clu PNT1a PNT1a-hyg PC-3-clu
PC-3-clu
PC-3-hyg
PC-3-hyg
A
B
a b c d e
f g h
i j k
PNT1a clones
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P CC H CC C H
Figure 2 Clusterin expression patterns in stable clones of PNT1a and PC-3. (A) Western blot detection. The upper panel, for each cell type, shows
clusterin detection in stable in clu clones (C) compared with hyg
r controls (H) and in parental cells (P). The lower panel provides an indication of total
proteins transferred to the PVDF membrane by Ponceau staining. (B) Immunocytochemical detection. Panels a–e show Alexa-green fluorescence to
visualise clusterin expression. Panel c (parental PNT1a) has been deliberately overexposed to reveal the weak cytoplasmic staining. Panels f and i show giant
cells from two different PC-3-clu clones actively expressing clusterin (green stain), note the multiple nuclei, counterstained by DAPI (blue stain). A phase-
contrast image of the giant cells is shown in panels g and j. Phase-contrast images of two different control PC-3 clones are shown in panels h and k.
Magnification:  400.
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sdetected with mouse monoclonal anti-hClusterin (see above).
Procaspase-9, cleaved poly-(ADP-ribose) polymerase (PARP) and
cleaved caspase-3 were detected with specific rabbit polyclonal
IgGs (New England Biolabs, Hitchin, UK). Cytokeratins were
detected with mouse monoclonal anti-pan-cytokeratin mixture
(Sigma, Dorset, UK).
The membranes were incubated in blocking solution (as above)
for 1h, then in primary antibody for 1h (clusterin) or overnight
(procaspase-9, cleaved PARP and cleaved caspase-3). After
4 10min washes in 0.1% Tween-20 in TBS (T-TBS), the mem-
branes were incubated in anti-mouse or anti-rabbit-peroxidase
(Sigma, Dorset, UK) diluted 1:5000 in blocking solution for
60min. The blots were washed 4 15min in T-TBS and detected by
chemiluminescence (BM chemiluminescence substrate, Boehringer,
Lewes, UK).
For protein staining Ponceau S solution 0.1% (wv
 1)i n5 %
acetic acid (Sigma, Dorset, UK) was used.
RESULTS
Clonogenicity of clusterin overexpressing cells
As shown in Figure 1, PNT1a transfected with pIRES-clu,
compared with PNT1a transfected with pIRES-hyg, resulted in a
significantly lower number of hygromycin-resistant colonies. The
pIRES-clu colony sizes were also generally smaller in diameter.
In transfected PC-3 cells, where drug selection was conducted
with 50mgml
 1 of hygromycin B, clusterin overexpression
produced more dramatic effects in terms of clonogenicity, since
both the number and the size of the derived colonies were
drastically reduced in comparison with the pIRES-hyg controls
(Figure 1). The percentage reduction of clonogenicity in cells
transfected with pIRES-clu was about 75% for PNT1a and 95% for
PC-3.
Characterisation of the stable clones
Individual colonies derived from PNT1a and PC-3, transfected
with both pIRES-clu (PNT1a-clu) and pIRES-hyg (PNT1a-hyg),
were isolated and expanded in the appropriate selection medium
to allow the measurement of clusterin levels and intracellular
distribution by Western blot (Figure 2A) and immunocytochem-
istry (Figure 2B). Some distinctive morphological features were
noted in the cells overexpressing exogenous clusterin. In
particular, PNT1a-clu cells tolerated different levels of vector-
expressed clusterin protein without any important morphological
changes, whereas surviving PC-3-clu clones were entirely resistant
to clusterin overexpression. Western blotting confirmed high
levels of intracellular clusterin (Figure 2A) and a diverse range of
clusterin expression levels in the individual clones.
The endogenous levels of clusterin expression in both PNT1a
and PC-3 were relatively low by both Western blotting (Figure 2A,
lanes P) and immunocytochemistry (Figure 2B), although the two
cell lines were chosen as they represented the situation in normal
and malignant tissues. As in prostate tissues, an immunohisto-
chemical signal was barely detectable in PNT1a, showing a
cytosolic localisation, and was normally undetectable in PC-3.
In all of the PNT1a-clu clones, expression of exogenous clusterin
was significantly higher compared to the endogenous clusterin
levels in the controls (PNT1a-hyg), but differences between the
single clusterin clones were observed. No predictable morpho-
logical changes correlated with these differences and, as described
below, no functional effects could be correlated to the variable
clusterin expression levels. Owing to the severe cytotoxicity, PC-3
clusterin clones (PC-3-clu) were expected to express relatively low
levels of this protein. Surprisingly, all five characterised PC-3-clu
clones showed a similarly strong clusterin expression compared to
the controls (PC-3-hyg), independently of the selection pressure
(Figure 2).
Despite the endogenous low levels of this protein and the
extensively limited tolerance to its overexpression exhibited during
drug selection, PC-3-clu clones were nevertheless able to survive in
the presence of large amounts of clusterin (Figure 2). During
selection, PC-3-clu cells underwent several rounds of karyokinesis
but were unable to overcome the G2–M phase, resulting in giant
cells that were neither senescent nor apoptotic while maintaining
high levels of clusterin expression. The stable PC-3-hyg clones
looked like normal PC-3 cells (data not shown).
Proliferation analysis of the stable clones
After cloning and 6 days of culture, the average number of PNT1a-
clu cells as assessed by WST-1 assay (to overcome problems
associated with counting multinucleate cells) was significantly
lower than PNT1a-hyg cells, showing a decrease of 50%
(Figure 3A). To further investigate whether this phenomenon
was due to blocked cell cycle or increasing cell progression or
increasing cell death, a monoparametric analysis by fluorescence-
activated cell sorter for each clone was performed (Figure 4A). The
200
300
400
500
600
700
800
900
1000
1100
1200
A
B
12 3
Days
45 6
100
200
500
400
300
600
123
Days
45 7 6
PNT1a-hyg
PNT1a-clu
PC-3-hyg
PC-3-clu
Figure 3 WST-1 proliferation analysis of representative stably trans-
formed clones. (A) Comparative proliferation rates of two representative
stably transformed PNT1a-clones. Red: PNT1a-hyg (from two analysed);
blue: PNT1a-clu (from four analysed). (B) Comparative proliferation rates
of PC-3 clones. Red: PC-3-hyg (from two analysed); blue: PC-3-clu (from
two analysed). Y-axis: OD at 450nm values correlate with the viable cell
numbers.
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sdata provide evidence of an increased apoptotic fraction (arrowed)
in four independent PNT1a-clu clones compared with both
PNT1a-hyg clones and PNT1a parental cells. Viable PNT1a-clu
cells did not show a significant variation of the cell cycle phases
compared to both controls and parental PNT1a cells, suggesting
that lower growth rate observed was very likely due only to
increased cell death.
For PC-3 cells, significant differences in viability/metabolic
capacity were evident when compared with controls (Figure 3B).
Fluorescence-activated cell sorter analysis of the stable PC-3-
clu clones indicated a two-fold rise in the G2/M fraction, while
PC-3-hyg clones had a cell cycle profile that was indistingui-
shable from parental PC-3 cells. In contrast, transient transfection
of PC-3 with the same clusterin expression plasmid (Figure 4B)
resulted in a 25% decrease of the G2–M phase, as we have
previously reported in transiently transfected PNT1a cells (Bettuzzi
et al, 2002).
Intracellular location of clusterin under apoptotic
conditions
The data presented above suggest that stable overexpression of
clusterin was sufficient to cause a decreased cell proliferation and
an increase in cell death for both PNT1a and PC-3. This was
accompanied by a nuclear translocation of the protein. To test this
hypothesis, we further investigated clusterin expression and its
localisation in response to chemical induction of apoptosis in these
two cell lines. Etoposide is a well-known topoisomerase II
inhibitor, widely used in cell biology to study apoptosis (Burden
et al, 1996). Treatment of both PNT1a and PC-3 cells with several
different concentrations of etoposide results within 12h in a strong
induction of apoptosis as assessed by Annexin-V binding, and a
marked increase of clusterin expression (Figure 5).
Intriguingly, we found considerable differences between these
two cell lines in terms of the activation of apoptotic pathways in
PNT1a-clu
PNT1a-hyg
PNT1a-hyg
PNT1a
PNT1a-clu
PNT1a-clu
PNT1a-clu
G2−M
26.3%
G2−M
27.7%
G2−M
21.9%
G2−M
22.7%
G2−M
22.6%
G2−M
23.8%
G2−M
25.0%
a
A
b
c
d
e
f
g
Figure 4 FACS analysis of stable and transient transfectants. (A) Cell cycle analysis of stable PNT-clu (four independent clones, a–d) and PNT-hyg (two
independent clones, e and f) in comparison with PNT1a parental cells (g). G2/M proportions are indicated for each cell type. Arrows indicate the presence
of increased (apoptotic) cellular debris in all four PNT1a-clu populations relative to PNT1a-hyg and parental PNT1a cells. (B) Cell cycle analysis of stable PC-
3-clu (two independent clones, a and b) and stable PC-3-hyg (c) in comparison with parental PC-3 cells (f) and PC-3 cells transiently transfected with pIRES-
clu (d) and pIRES-hyg (e). G2/M proportions are indicated for each cell type.
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sresponse to the DNA breaks induced by etoposide. Indeed, PNT1a
cells showed a marked caspase-3 cleavage and subsequent PARP
activation, while apoptosis in PC-3 cells was apparently caspase-
independent (Figure 5). By immunocytochemistry (Figure 5,
panels d and h), a clear nuclear localisation of clusterin was
observed in virtually every cell after etoposide treatment. There-
fore, expression of clusterin and its migration to the nucleus
appeared to be one of the earliest events in PNT1a and PC-3 cells
undergoing apoptosis.
Molecular features of apoptosis in response to stabilised
clusterin expression
To assess apoptotic cascades in the PNT1a and PC-3 stable clones,
the expression of procaspase-9, cleaved caspase-3 and cleaved
PARP were measured by Western blot. In both PNT1a and PC-3-
clu clones, cleaved caspase-3 was undetectable. Between PNT1a-clu
clones, although no differences in cleavage of PARP were observed,
a decrease of procaspase-9 was however detected, while the PC-3-
clu clones did not reveal significant variations of these two
markers when compared to the controls (Figure 6B).
Cleavage of PARP has been shown to be a valid marker for
apoptosis in PC-3 cells (Chinni et al, 2001; Voelkel-Johnson et al,
2002). In PC-3-clu cells, a significant reduction of cleaved PARP
was found relative to PC-3-hyg (Figure 6B) showing a possible
mechanism of resistance to apoptosis.
DISCUSSION
Previous studies carried out in nonmalignant PNT1a cells have
demonstrated that a transient overexpression of clusterin is able to
slow down the cell cycle (Bettuzzi et al, 2002). Since endogenous
clusterin can be (barely) detected in the PNT1a cells, we sought to
reproduce this result in PC-3 cells, malignant prostate epithelial
cells in which endogenous clusterin is almost undetectable by
Western blot. Transient expression of clusterin in PC-3 cells
confirmed a cell cycle arrest, but distinct from that observed in
PNT1a (Bettuzzi et al, 2002). No clearly classical activation of
apoptotic pathways was recognised in PC-3 under this temporary
high level of clusterin expression.
More homogeneous levels of clusterin expression within a cell
can be achieved by establishment of stable cell lines. However, with
both prostate cell lines, the generation of permanent cell lines
engineered to overexpress clusterin proved difficult. By employing
the IRES strategy in which drug resistance is directly linked to
the expression of the exogenous clusterin, a number of rare,
independently derived clusterin expressing clones were isolated
from both cell lines. We have previously employed this strategy to
examine the biological consequences of PTEN expression in these
cell types (Sharrard and Maitland, 2000). There was a significantly
higher yield of clones from PNT1a cells, which express higher
levels of endogenous clusterin, compared to PC-3 cells. However,
as shown in Figure 3, slower population doubling times were a
common characteristic of the clusterin transformants, but essential
morphological differences were found between PC-3 and PNT1a
clones.
PC-3-clu cells maintained the features developed during
selection. PNT1a-clu clones did not exhibit any significant
morphological difference compared to the controls and main-
tained signs of functional apoptotic pathways. The differences
shown by PC-3 cells, relative to PNT1a, could be due to the more
aggressive phenotype of androgen-independent PC-3 cells, which
would make apoptosis induction more difficult, whereas PNT1a
cells, although immortalised with large T of SV40, are more
differentiated and not tumorigenic (Cussenot et al, 1991).
Paradoxically, the PNT1a-clu clones, despite higher levels of the
endogenous protein and the higher colony-forming efficiency,
PC-3-clu
PC-3-clu
PC-3-hyg
PC-3
G2−M
32.3%
G2−M
42.8%
G2−M
19.2%
G2−M
21.8%
G2-M 20.4%
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Figure 4 Continued
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srevealed relatively lower clusterin expression compared with PC-3-
clu cells. This apparent contradiction could be explained by a form
of resistance acquired by PC-3-clu survivors to the high levels of
clusterin. One distinction between PC-3-clu and PNT1a-clu cells is
highlighted in Figure 6 where, in PNT1a-clu clones, the relatively
low level of procaspase-9, together with the data obtained by FACS
analysis (Figure 4A), suggest that a limited apoptotic activity in
PNT1a-clu clones has been maintained. PC-3-clu cells, on the
contrary, required a precise mechanism to escape apoptosis, and a
capacity to by-pass PARP cleavage may explain survival in the
presence of elevated levels of clusterin. These data are apparently
in contrast with the report by Zellweger et al (2003), who recently
described an extended protection against radiation-induced cell
death in stable transfected LNCaP cells overexpressing clusterin.
Zellweger et al hypothesised that upregulation of this protein can
represent an adaptive cell-survival mechanism on the basis of their
previous observation that clusterin is overexpressed in prostate
cancer (Miyake et al, 2000). This observation was not confirmed by
our (Bettuzzi et al, 2000; Scaltriti et al, 2004; Caporali et al, 2004)
and other publications (Stuart et al, 2004), demonstrating that
clusterin is indeed more frequently downregulated in prostate
cancer. Moreover, we have provided evidence to show that only
PC-3 cells surviving to clonogenic selection, and thus exhibiting an
apoptosis-resistance phenotype, can tolerate high levels of
clusterin expression. Accordingly, the acquisition of resistance to
apoptosis by PC-3 cells can be envisaged as an event that is
necessary to survive clusterin overexpression, and not the
opposite.
Thus, an alternative explanation for the same phenomenon
could be that the apoptosis-resistance features acquired by PC-3-
clu cells are consequent to previous clonogenic selection, and
PNT1a PC-3
123 123
Cleaved caspase-3
Cleaved PARP
Clusterin
Cytokeratins
A
B
CG
DH
F
E
Figure 5 Etoposide-mediated effects on clusterin expression in PNT1a
and PC-3 cells. Western blot detection of clusterin expression, cleaved
caspase-3 and cleaved PARP in PNT1a (A) and PC-3 (E) cells. Equal
protein loading was confirmed by pan-cytokeratin detection. Lanes 1:
parental untransfected cells; lanes 2: parental cells treated overnight with
200mM etoposide; lanes 3: parental cells treated overnight with 400mM
etoposide. PNT1a and PC-3 treated overnight with 400mM etoposide
(phase images B and F) were tested for Annexin-V staining (respectively,
C and G) and clusterin immunostaining (respectively, D and H).
Magnification:  400.
PNT1a-clu
PNT1a clones PC-3 clones
PC-3-clu
C C CHH C C C H H
Procaspase-9
Cleaved PARP
Pan-cytokeratin
A
B
Figure 6 Phenotype of PNT1A and PC-3 cells expressing clusterin.(A)
Alexa-green fluorescence visualisation of clusterin localisation in PNT1a-clu
cells (upper left) and PC-3-clu cells (upper right). The same images are
shown, merged with DRAQ 5 red counterstaining (lower left) and with
DAPI blue counterstaining (lower right). Magnification:  400. (B)
Procaspase-9 and cleaved PARP detected by Western blot in PNT1a-clu
and PC-3-clu clones (C) as compared to PNT1a-hyg and PC-3-hyg clones
(H). Equal protein loading was confirmed by pan-cytokeratin detection.
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stherefore these clones are the result of clusterin overexpression-
escaped cell death.
A further variation of clusterin expression pattern in clu clones
was detected by immunocytochemistry, where the protein was
found to be located, in contrast to the normal cytoplasmic
localisation, in both the nucleus and cytoplasm (Figures 2 and 6A).
Recently, a nuclear form of clusterin, which lacks the secretion
signal as a result of an alternative splicing, was described by
Leskov et al (2003) after treating cells with ionising radiation. This
particular form becomes specifically located in the cell nucleus,
and is responsible for cell death. However, in the presence of high
intracellular clusterin expression, the protein (which contains at
least two NLS) could enter into the nucleus even without a
requirement for splicing. Therefore, the nuclear relocalisation of
clusterin in both PNT1a-clu and PC-3-clu clones was not
unexpected. By silencing the expression of clusterin gene using
small interfering RNA (siRNA), Trougakos et al (2004) showed
that the selective knock down of the secreted form of this protein
induced apoptosis in PC-3 cells. Surprisingly, the siRNA approach
did not exert significant effects on intracellular clusterin. This
finding indirectly suggests that clusterin might act differently
depending on its subcellular localisation. Indeed, in a more recent
work, the same authors reported cytotoxic properties of this
protein when accumulated in high amounts intracellularly
(Trougakos and Gonos, 2004).
To further establish the link between apoptosis and intracellular
clusterin location, we carried out the inverse experiment to localise
clusterin expression within both PNT1a and PC-3 cells, after
etoposide-induced apoptosis. After 12h of etoposide treatment,
increased clusterin expression was observed in a dose-dependent
manner, in both PNT1a and PC-3 cells (Figure 5) by both Western
blot (Figure 5A and E) and immunocytochemistry (Figure 5D and
H). Etoposide treatment therefore not only upregulates clusterin
expression but also drives its localisation into the nucleus of
virtually all of the treated cells. This correlates with an increase in
cell rounding, detection of Annexin-V and, in PNT1a cells,
activation and cleavage of caspase-3 and PARP.
Taken together, the etoposide and stable clusterin overexpres-
sion data would suggest that clusterin translocation into the cell
nucleus, where it can interact with gene products involved in cell
cycle regulation, DNA repair (Yang et al, 1999) and/or pro-
grammed cell death, plays a central role in its biological activity
(Yang et al, 2000; Leskov et al, 2003). An analysis of the expression
levels of cell cycle-related proteins such as cyclin A, cyclin B and
p27 by Western blot after manipulation of clusterin levels was,
however, inconclusive.
We conclude that, although the PNT1a and PC-3 cells respond
differently to clusterin overexpression, this protein primarily
affects cell cycle progression while activating different apoptotic
pathways according to cell type, including a caspase-3-indepen-
dent mechanism (Han et al, 2003). However, in PC-3 cells, which
express only minimal levels of endogenous clusterin, precise
apoptosis inhibitory mechanisms, such as resistance to cleavage of
PARP, are required to overcome this phenomenon. Such
antiapoptotic mechanisms may provide the basis for prostate
tumour resistance to many conventional therapies. Further study
of the clusterin-resistant PC-3 cells and a comparison to wild type
should provide further evidence of the molecular basis of tumour
resistance to apoptosis induction.
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